IRONWOOD PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $0 as of 2023-12-31, per its 10-K filed 2024-02-16.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2024-02-16
- 2023-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2023-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2023-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2023-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-16 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 |
| 2022-12-31 | $19.00K 10-K · filed 2024-02-16 |
| 2022-09-30 | $1.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $152.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $899.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.32M 10-K · filed 2024-02-16 |
| 2021-09-30 | $5.49M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $11.06M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $7.98M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $12.09M 10-K · filed 2023-02-16 |
| 2019-12-31 | $24.26M 10-K · filed 2022-02-18 |
| 2018-12-31 | $33.76M 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |